December 9, 2015Open Access

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Should DTG + 3TC demonstrate high rates of virologic suppression, this regimen will be cost-effective and would save >500 million in ART costs in the United States over 5 years.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Girouard et al. (Wed,) studied this question.

synapsesocial.com/papers/69d856e452654bb436d19241 https://doi.org/https://doi.org/10.1093/cid/civ981

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients2008 · 137 citations
2Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services.1998 · 238 citations
3Class-Sparing Regimens for Initial Treatment of HIV-1 Infection2008 · 675 citations
4Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy1998 · 316 citations
5Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care2012 · 160 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo